Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/mortality? Yes

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2009 Oct 31

PMID 19875578

Citations 9

Authors

Cristina Bianchi

Roberto Miccoli

Giuseppe Daniele

Giuseppe Penno

Stefano Del Prato

Affiliations

Soon will be listed here.

Citing Articles

Postoperative short-term mortality between insulin-treated and non-insulin-treated patients with diabetes after non-cardiac surgery: a systematic review and meta-analysis.

Jiang J, Wang S, Sun R, Zhao Y, Zhou Z, Bi J Front Med (Lausanne). 2023; 10:1142490.

PMID: 37200964 PMC: 10185903. DOI: 10.3389/fmed.2023.1142490.

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China.

Men P, Liu T, Zhai S Diabetes Metab Syndr Obes. 2020; 13:2823-2831.

PMID: 32848438 PMC: 7431175. DOI: 10.2147/DMSO.S266901.

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.

Hanefeld M, Traylor L, Gao L, Landgraf W Cardiovasc Diabetol. 2017; 16(1):66.

PMID: 28526014 PMC: 5438574. DOI: 10.1186/s12933-017-0548-0.

Pathophysiology and Medical Treatment of Carotid Artery Stenosis.

Prasad K Int J Angiol. 2015; 24(3):158-72.

PMID: 26417183 PMC: 4572017. DOI: 10.1055/s-0035-1554911.

Coronary artery disease and diabetes mellitus.

Aronson D, Edelman E Cardiol Clin. 2014; 32(3):439-55.

PMID: 25091969 PMC: 4672945. DOI: 10.1016/j.ccl.2014.04.001.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D . Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; (3):CD002966. DOI: 10.1002/14651858.CD002966.pub3. View

Nathan D, Buse J, Davidson M, Ferrannini E, Holman R, Sherwin R . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 32(1):193-203. PMC: 2606813. DOI: 10.2337/dc08-9025. View

Stamler J, Vaccaro O, Neaton J, Wentworth D . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2):434-44. DOI: 10.2337/diacare.16.2.434. View

Bianchi C, Penno G, Pancani F, Civitelli A, Piaggesi A, Caricato F . Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 78(2):246-53. DOI: 10.1016/j.diabres.2007.03.020. View

Evans J, Ogston S, Emslie-Smith A, Morris A . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006; 49(5):930-6. DOI: 10.1007/s00125-006-0176-9. View

Nikolaidis L, Mankad S, Sokos G, Miske G, Shah A, Elahi D . Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109(8):962-5. DOI: 10.1161/01.CIR.0000120505.91348.58. View

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

10.

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

11.

Stone P, Muller J, Hartwell T, York B, Rutherford J, Parker C . The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989; 14(1):49-57. DOI: 10.1016/0735-1097(89)90053-3. View

12.

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

13.

Almdal T, Scharling H, Skov Jensen J, Vestergaard H . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13):1422-6. DOI: 10.1001/archinte.164.13.1422. View

14.

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

15.

Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316(7134):823-8. PMC: 28484. DOI: 10.1136/bmj.316.7134.823. View

16.

Cefalu W . Glycemic targets and cardiovascular disease. N Engl J Med. 2008; 358(24):2633-5. DOI: 10.1056/NEJMe0803831. View

17.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

18.

McGuire D, Inzucchi S . New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation. 2008; 117(3):440-9. DOI: 10.1161/CIRCULATIONAHA.107.704080. View

19.

Home P, Pocock S, Beck-Nielsen H, Gomis R, Hanefeld M, Jones N . Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007; 357(1):28-38. DOI: 10.1056/NEJMoa073394. View

20.

Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. DOI: 10.1016/S0140-6736(05)67528-9. View